Showing 4301-4310 of 7103 results for "".
- FDA Cracks Down on Energy-Based Vaginal Rejuvenationhttps://practicaldermatology.com/news/fda-cracks-down-on-vaginal-rejuvenation/2457667/The FDA is cracking down on the use energy-based devices to perform vaginal 'rejuvenation.' The use of such devices to perform vaginal "rejuvenation," cosmetic vaginal procedures, or non-surgical vaginal procedures to treat symptoms related to menopause, urinary incontin
- LEO Pharma to Acquire Bayer Prescription Dermatology Businesshttps://practicaldermatology.com/news/leo-pharma-to-acquire-bayer-prescription-dermatology-business/2457666/LEO Pharma has entered into a definitive agreement to buy Bayer's global prescription dermatology unit. The portfolio to be acquired includes branded topical prescription treatments for acne, fungal skin infections, and rosacea and a range of topical steroids with an annual turnover in 2017 o
- Link Between Diet and Skin Disease Takes Center Stage at Summer AADhttps://practicaldermatology.com/news/link-between-diet-and-skin-disease-takes-center-stage-at-summer-aad/2457672/Dermatologists must help patients determine if there are any foods that may cause their skin condition to flare and provide evidence-based recommendations about next steps. “People looking to improve their skin health may think that changing their diet is the answer, but a derm
- Pulse Biosciences: First Patients Treated in Study of Sebaceous Hyperplasia Lesionshttps://practicaldermatology.com/news/pulse-biosciences-first-patients-treated-in-study-of-sebaceous-hyperplasia-lesions/2457682/Pulse Biosciences, Inc. says the first patients have been treated in its multi-center study to evaluate the safety and efficacy of its Nano-Pulse Stimulation (NPS) technology for eliminating Sebaceous Hyperplasia (SH). SH is an unsightly benign skin lesion that typically appears on facial skin an
- BioPharmX: FDA Grants CARC Waiver; Post-Hoc Analysis for BPX-01 Completehttps://practicaldermatology.com/news/biopharmx-fda-grants-carc-waiver-post-hoc-analysis-for-bpx-01-complete/2457686/The FDA has waived its requirement for a dermal carcinogenicity study for BPX-01 from BioPharmX Corporation, eliminating several years of non-clinical research normally required for FDA review. BPX-01, a novel topical gel formulation of minocycline for the treatment of inflammatory
- AD Takes Big Toll on QOLhttps://practicaldermatology.com/news/ad-takes-a-big-toll-on-qol/2457691/Itch, dryness and other eczema symptoms negatively affect quality of life, according to a new study published in the Annals of Allergy, Asthma and Immunology. Of 602 adults with eczema, symptoms that were the bigg
- Cutera's New truSculpt iD Offers Personalized Body Sculptinghttps://practicaldermatology.com/news/cuteras-new-trusculpt-id-offers-personalized-body-sculpting/2457693/Cutera, Inc's new truSculpt® iD offers an evolution in body sculpting with unique hands-free capability and the ability to treat a full abdomen in as little as 15 minutes. truSculpt iD offers physicians and other qualified practitioners the flexibility to deliver personalized body sculpti
- BrightGuard Installs Free Sunscreen Dispensers at New York City Public Pools and Beacheshttps://practicaldermatology.com/news/brightguard-installs-free-sunscreen-dispensers-at-new-york-city-public-pools-and-beaches/2457708/Through its ongoing partnership with non-profit sponsor and donor IMPACT Melanoma and sunscreen provider Coppertone, BrightGuard has installed 134 sunscreen dispensers throughout New York City (NYC) public pools and beaches. BrightGuard—the first aut
- FDA Approves Braftovi in Combination with Mektovi for Advanced BRAF-mutant Melanomahttps://practicaldermatology.com/news/fda-approves-of-braftovi-in-combination-with-mektovi-for-advanced-braf-mutant-melanoma/2457710/The FDA has approved Array BioPharma Inc.'s BRAFTOVI (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by a
- New Patient-Centered Panel Helps BioPharmX Define its Role in the Future of Dermatologyhttps://practicaldermatology.com/news/new-patient-centered-panel-helps-biopharmx-define-its-role-in-the-future-of-dermatology/2457721/BioPharmX Corporation has formed a Special Advisory Council of thought leaders from various disciplines to help the company embrace patient centricity in its products, pricing, and market access considerations. The advisors, who bring decades of experience in fields beyond dermatology&mda